An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer
Latest Information Update: 10 Jan 2025
At a glance
- Drugs AB 1015 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man
- Sponsors ArsenalBio
- 06 May 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Dec 2024.
- 06 May 2024 According to an ArsenalBio media release, data from this study will be highlighted at the American Society of Gene + Cell Therapy (ASGCT) annual meeting
- 05 Jan 2023 According to an ArsenalBio media release, an update inclusive of information about the clinical trial will be provided during the company's upcoming presentation at the 41st Annual J.P. Morgan Healthcare Conference.